The MMV Imperative

Defeating Malaria Together

David Reddy, CEO, MMV
World Health Summit, Berlin
A decade of MMV mission working in partnership to discover, develop and facilitate access to new medicines for malaria.

140 partners

45 countries
PDP model
Proven path for antimalarial drug development

- Academic research and clinical trial sites
- Pharmaceutical research
- New medicines malaria

Donors and in-kind contributions
50 projects including:

- 2 medicines launched
- 2 medicines undergoing regulatory approval
- 2 medicines currently in clinical studies
- 2 compounds that will enter clinical studies by year-end
TPPs aligned to R&D priorities

• Patients at the centre
  - Children
  - Pregnant women
  - Severe malaria patients

• Medicines that make a difference
  - Single-dose cure – compliance
  - Counter resistance
  - Inexpensive and stable

• The end game: Eradication
  - Liver-stage cure
  - Transmission blockers
  - Chemo-prevention
Rigorous portfolio management

- Broad portfolio
- Demanding target profiles
- Rigorous scientific review
- ‘Pruning’ of non-aligned projects
Building upon success

The secrets to MMV’s success:

• Global partnership network connecting R&D experts worldwide
• Portfolio of drugs, some of which are saving lives today
• In-house discovery, development and delivery expertise
• Cost-effective, efficient allocation of funds
• Rigorous portfolio management
• Risk sharing across all sectors

“MMV shows how the market can work for the world’s poorest people.”
Melinda Gates